STOCK TITAN

Maravai Lifesciences (NASDAQ: MRVI) counsel gets 776 ESPP shares

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Maravai LifeSciences Holdings, Inc. reported that General Counsel Kurt Oreshack acquired 776 shares of Class A Common Stock at $2.84 per share. These shares were obtained through the company’s 2020 Employee Stock Purchase Plan and the transaction was exempt under Rule 16b-3.

Following this grant/award acquisition, Oreshack directly holds a total of 385,767 shares of Class A Common Stock. This is a routine compensation-related purchase rather than an open-market buy or sale.

Positive

  • None.

Negative

  • None.
Insider ORESHACK KURT
Role General Counsel
Type Security Shares Price Value
Grant/Award Class A Common Stock 776 $2.84 $2K
Holdings After Transaction: Class A Common Stock — 385,767 shares (Direct)
Footnotes (1)
  1. F1. The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 776 shares of Class A Common Stock was exempt pursuant to Rule 16b-3.
Shares acquired 776 shares Class A Common Stock grant/award acquisition
Acquisition price $2.84 per share Price under 2020 Employee Stock Purchase Plan
Total holdings after transaction 385,767 shares Direct ownership following ESPP acquisition
Acquire transactions in filing 1 transaction Form 4 transaction summary acquireCount
Employee Stock Purchase Plan financial
"pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Rule 16b-3 regulatory
"The acquisition of those 776 shares of Class A Common Stock was exempt pursuant to Rule 16b-3"
Rule 16b-3 is a Securities and Exchange Commission regulation that exempts certain routine, pre-approved transactions by company insiders from automatic liability for short-term trading profits. It acts like a safe harbor: if an insider follows a formal plan or the board approves specific transactions in advance, profits from buying and selling company stock within six months are not automatically reclaimed. Investors care because the rule clarifies when insider trades are permissible and reduces uncertainty about potential clawbacks.
Class A Common Stock financial
"acquisition of shares of the Issuer's Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Maravai Lifesciences (MRVI) report for Kurt Oreshack?

Maravai Lifesciences reported that General Counsel Kurt Oreshack acquired 776 shares of Class A Common Stock. The shares were obtained through the 2020 Employee Stock Purchase Plan as a routine compensation-related transaction exempt under Rule 16b-3, rather than an open-market purchase or sale.

At what price were the new Maravai Lifesciences (MRVI) shares acquired by the general counsel?

The 776 newly acquired Maravai Lifesciences shares were purchased at $2.84 per share. This price applied within the company’s 2020 Employee Stock Purchase Plan, which is a standard employee benefit program rather than an open-market trade on a stock exchange.

How many Maravai Lifesciences (MRVI) shares does Kurt Oreshack hold after this Form 4?

After this transaction, General Counsel Kurt Oreshack directly holds 385,767 shares of Maravai’s Class A Common Stock. This total reflects the addition of 776 shares acquired through the 2020 Employee Stock Purchase Plan, as disclosed in the Form 4 insider filing.

Was the Maravai Lifesciences (MRVI) insider transaction under a compensation or trading plan?

The reported insider transaction was made under Maravai’s 2020 Employee Stock Purchase Plan. This indicates a compensation-related share acquisition, not an open-market trading decision, and the filing notes the transaction was exempt from certain rules under Rule 16b-3.

What does Rule 16b-3 exemption mean for the Maravai Lifesciences (MRVI) insider trade?

The Rule 16b-3 exemption means the 776-share acquisition is treated as a compensatory transaction approved under SEC rules. Such grants or purchases under company plans typically avoid short-swing profit rules, distinguishing them from discretionary open-market trades by insiders.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
ORESHACK KURT

(Last)(First)(Middle)
C/O MARAVAI LIFESCIENCES HOLDINGS, INC.
10770 WATERIDGE CIRCLE, SUITE 200

(Street)
SAN DIEGO CALIFORNIA 92121

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
MARAVAI LIFESCIENCES HOLDINGS, INC. [ MRVI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
General Counsel
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock05/15/2026A(1)V776A$2.84385,767D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The Reporting Person is voluntarily reporting the acquisition of shares of the Issuer's Class A Common Stock pursuant to the Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan. The acquisition of those 776 shares of Class A Common Stock was exempt pursuant to Rule 16b-3.
Remarks:
/s/ Kurt Oreshack05/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)